This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

51/100

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Tau biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

Background It is unknown whether multidomain interventions, which might preserve late-life cognition, affect Alzheimer's disease pathology. Previous studies measured cerebrospinal fluid and imaging Alzheimer's disease biomarkers in small subsamples of multidomain trial participants. Newly developed assays enable the measurement of blood-based Alzheimer's disease biomarkers in larger samples.

What this study adds

Evidence grade: High

The record lists 527 participants. This secondary analysis of a randomized controlled trial assessed whether a blood marker, plasma p-tau181, could detect or predict the effects of a multidomain intervention on dementia prevention. It does not report whether the intervention itself prevented dementia, only whether the marker was useful.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Coley, N., Zetterberg, H., Cantet, C., Guyonnet, S., Ashton, N. J., Vellas, B., et al. (2024). Plasma p-tau181 as an outcome and predictor of multidomain intervention effects: a secondary analysis of a randomised, controlled, dementia prevention trial. The lancet. Healthy longevity. https://doi.org/10.1016/s2666-7568(23)00255-6

Vancouver

Coley N, Zetterberg H, Cantet C, Guyonnet S, Ashton NJ, Vellas B, et al. Plasma p-tau181 as an outcome and predictor of multidomain intervention effects: a secondary analysis of a randomised, controlled, dementia prevention trial. The lancet. Healthy longevity. 2024. doi:10.1016/s2666-7568(23)00255-6. PMID: 38310892.

BibTeX

@article{coley2024-38310892,
  author  = {Coley, N. and Zetterberg, H. and Cantet, C. and Guyonnet, S. and Ashton, N. J. and Vellas, B. and Blennow, K. and Andrieu, S. and others},
  title   = {{Plasma p-tau181 as an outcome and predictor of multidomain intervention effects: a secondary analysis of a randomised, controlled, dementia prevention trial}},
  journal = {The lancet. Healthy longevity},
  year    = {2024},
  doi     = {10.1016/s2666-7568(23)00255-6},
  pmid    = {38310892},
  url     = {https://doi.org/10.1016/s2666-7568(23)00255-6}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record lists 527 participants. Ask whether that is enough for the question, and who they were.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded high. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. High means the abstract mentions a randomized design, a meta-analysis or a systematic review. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Previous studies measured cerebrospinal fluid and imaging Alzheimer's disease biomarkers in small subsamples of multidomain trial participants.
Newly developed assays enable the measurement of blood-based Alzheimer's disease biomarkers in larger samples.
We aimed to assess whether plasma tau phosphorylated at threonine 181 (p-tau181) was able to detect or predict 3-year multidomain intervention effects.
Methods This is a secondary analysis of the randomised, controlled, Multidomain Alzheimer Prevention Trial (MAPT) testing a 3-year multidomain intervention, omega-3 fatty acid supplementation, or both versus placebo, in individuals aged 70 years and older in 13 memory centres in France and Monaco.

Why it matters

This secondary analysis of a randomized controlled trial assessed whether a blood marker, plasma p-tau181, could detect or predict the effects of a multidomain intervention on dementia prevention. It does not report whether the intervention itself prevented dementia, only whether the marker was useful.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Participants527
Evidence strengthHigh

How this study scored 51/100

Published in a leading specialty journal. Scored zero for study design and effect reported because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (The lancet. Healthy longevity)
Journal's citation record	1 / 4	The Lancet Healthy Longevity: journal h-index 78 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	5 / 5	Rated “high” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2024 — within 3 year(s) of the newest study here
Sample size	2 / 4	527 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	1 / 2	Randomized (as stated in the record)
Times cited	2 / 7	Cited 10 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	2.5 citations a year over 4 year(s) since 2024
Impact for its field and year	2 / 6	Cited 2.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 4 other studies in this library
Still being cited	1 / 4	Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	1 / 4	Last-listed author Ali Bouhayia: h-index 13 (OpenAlex, whole career)
Institution's track record	2 / 3	University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration	3 / 3	OpenAlex lists 15 institution(s) in 5 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 38310892)
Free to read	0 / 2	Behind a paywall — scores zero
Total	51 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Tau biomarkers from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →